FAST III : 95% Enrollment

Exciting News Update: FAST III Trial Reaches 95% Enrollment Milestone!

The FAST III trial, which compares vFFR versus FFR guided revascularization, has successfully enrolled 95% of its target participants. With up to 2,228 patients across 7 countries and over 40 centers. 

We extend our gratitude to Principal Investigator Joost Daemen, all site investigators, the ECRI - European Cardiovascular Research Institute, and our partner Siemens Healthineers for their dedication in reaching this milestone.

For full study details, visit: FAST III Trial Details